BE903128A - Derives de benzimidazole procede pour leur preparation et agents anti-ulceres en contenant - Google Patents

Derives de benzimidazole procede pour leur preparation et agents anti-ulceres en contenant

Info

Publication number
BE903128A
BE903128A BE0/215506A BE215506A BE903128A BE 903128 A BE903128 A BE 903128A BE 0/215506 A BE0/215506 A BE 0/215506A BE 215506 A BE215506 A BE 215506A BE 903128 A BE903128 A BE 903128A
Authority
BE
Belgium
Prior art keywords
group
preparation
agents containing
benzimidazole derivatives
hydrogen atom
Prior art date
Application number
BE0/215506A
Other languages
English (en)
Original Assignee
Nippon Chemiphar Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from JP59182400A external-priority patent/JPS6160660A/ja
Priority claimed from JP60061195A external-priority patent/JPH0764826B2/ja
Priority claimed from JP60061194A external-priority patent/JPH068283B2/ja
Application filed by Nippon Chemiphar Co filed Critical Nippon Chemiphar Co
Publication of BE903128A publication Critical patent/BE903128A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/28—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/26—Oxygen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Des dérives de benzimodazole de formule (I) dans laquelle R1 représente un atome d'hydrogène, un groupe alkyle en C1-C8, un groupe cycloalkyle, un groupe phényle ou un groupe aralkyle, R2 représente un atome d'hydrogène ou un groupe alkyle en C1-C8, ou encore R1 et R2 forment un noyau ensemble avec l'atome d'azote adjacent, tandis que R3 et R4 représentent chacun un atome d'hydrogène, un atome d'halogène, un groupe trifluorométhyle, un groupe alkyle inférieur, un groupe alcoxy inférieur, un groupe alcoxy inférieur-carbonyle ou un groupe amino, ces dérivés étant efficaces contre les ulcères.
BE0/215506A 1984-08-31 1985-08-27 Derives de benzimidazole procede pour leur preparation et agents anti-ulceres en contenant BE903128A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP59182400A JPS6160660A (ja) 1984-08-31 1984-08-31 ベンズイミダゾ−ル誘導体およびその製造法ならびにこれを含有する抗潰瘍剤
JP60061195A JPH0764826B2 (ja) 1985-03-26 1985-03-26 ベンズイミダゾール誘導体
JP60061194A JPH068283B2 (ja) 1985-03-26 1985-03-26 ベンズイミダゾ−ル誘導体およびその製造法ならびにこれを含有する抗潰瘍剤

Publications (1)

Publication Number Publication Date
BE903128A true BE903128A (fr) 1985-12-16

Family

ID=27297422

Family Applications (1)

Application Number Title Priority Date Filing Date
BE0/215506A BE903128A (fr) 1984-08-31 1985-08-27 Derives de benzimidazole procede pour leur preparation et agents anti-ulceres en contenant

Country Status (14)

Country Link
KR (1) KR920004936B1 (fr)
AR (1) AR242195A1 (fr)
AU (3) AU4640985A (fr)
BE (1) BE903128A (fr)
BR (1) BR8504252A (fr)
CH (1) CH665417A5 (fr)
DE (1) DE3531487C2 (fr)
ES (1) ES8703142A1 (fr)
FR (1) FR2569691B1 (fr)
GB (1) GB2163747B (fr)
IT (1) IT1189601B (fr)
MX (1) MX159807A (fr)
NL (1) NL8502384A (fr)
SE (1) SE500669C2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687775A (en) * 1986-07-17 1987-08-18 G. D. Searle & Co. 2-[(Imidazo[1,2-a]pyridinylmethyl)sulfinyl]-1H-benzimidazoles
US4721718A (en) * 1986-08-18 1988-01-26 G. D. Searle & Co. 2-[(imidazo[1,2-a]pyridin-3-ylmethyl)sulfinyl]-1H-benzimidazoles useful in the treatment and prevention of ulcers
US4772619A (en) * 1986-07-17 1988-09-20 G. D. Searle & Co. [(1H-benzimidazol-2-ylsulfinyl)methyl]-2-pyridinamines

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8417194D0 (en) * 1984-07-05 1984-08-08 Boots Co Plc Therapeutic agents
GB2161160B (en) * 1984-07-06 1989-05-24 Fisons Plc Heterocyclic sulphinyl compounds
EP0174717B1 (fr) 1984-07-06 1992-01-22 FISONS plc Benzimidazoles, et leur préparation, formulation et application comme inhibiteur de sécrétion d'acide gastrique
US5869513A (en) * 1985-05-24 1999-02-09 G. D. Searle & Co. 2- (1H-benzimidazol-2-ylsulfinyl)methyl!benzenamines
AU5768886A (en) * 1985-05-24 1986-11-27 G.D. Searle & Co. 2-((1-h-benzimidazol-2-ylsulfinyl)methyl)benzenamines
US4824856A (en) * 1985-08-14 1989-04-25 Nippon Chemiphar Co., Ltd. Method of protecting gastrointestinal tract
EP0232399A1 (fr) * 1985-08-21 1987-08-19 Byk Gulden Lomberg Chemische Fabrik GmbH Nouvelles amines, leur procede de fabrication, leur utilisation, et medicaments les contenant
AR243167A1 (es) 1985-08-24 1993-07-30 Hoechst Ag Procedimiento para la preparacion de toluidinas sustituidas.
AU619444B2 (en) * 1986-06-02 1992-01-30 Nippon Chemiphar Co. Ltd. 2-(2-aminobenzylsulfinyl)- benzimidazole derivatives
EP0251536A1 (fr) * 1986-06-24 1988-01-07 FISONS plc Benzimidazoles, leur préparation, formulation et utilisation comme inhibiteurs de sécrétion d'acide gastrique
DE3639926A1 (de) * 1986-11-22 1988-06-01 Hoechst Ag Substituierte thienoimidazoltoluidin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zubereitungen und ihre verwendung als magensaeuresekretionshemmer
IT1222412B (it) * 1987-07-31 1990-09-05 Chiesi Farma Spa Tiometil e sulfinil metil derivati ad azione antisecretiva acida gastrica,loro procedimento di preparazione e composizioni farmaceutiche che li contengono
JP2614756B2 (ja) * 1988-08-10 1997-05-28 日本ケミファ株式会社 イミダゾール誘導体およびその製造法ならびにこれを含有する抗潰瘍剤
JPH06298611A (ja) * 1993-04-16 1994-10-25 Nippon Chemiphar Co Ltd 抗菌剤
SE9301489D0 (sv) 1993-04-30 1993-04-30 Ab Astra Veterinary composition
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
HRP960232A2 (en) * 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
ES2236628T3 (es) * 1995-09-21 2005-07-16 Pharma Pass Ii Llc Composicion farmaceutica que contiene un omeprazol labil de acido, y procedimiento para su preparacion.
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
US6599927B2 (en) 1996-10-11 2003-07-29 Astrazeneca Ab Use of an H+, K+-ATPase inhibitor in the treatment of Widal's Syndrome
WO1999004816A1 (fr) 1997-07-25 1999-02-04 Byk Gulden Lomberg Chemische Fabrik Gmbh Inhibiteur de la pompe a protons en combinaison therapeutique avec des substances antibacteriennes
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
ES2262335T3 (es) 1998-08-12 2006-11-16 Altana Pharma Ag Forma de administracion oral para piridin-2-ilmetilsulfinil-1h-bencimidazoles.
WO2000027841A1 (fr) * 1998-11-06 2000-05-18 Dong-A Pharmaceutical Co., Ltd. Procede de preparation de derives de sulfure
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
YU86001A (sh) 1999-06-07 2004-07-15 Altana Pharma Ag. Novi preparat i oblik, u kojem se daje lek, koji sadrži aktivno jedinjenje labilno prema kiselini
SE9903831D0 (sv) * 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
JP4698950B2 (ja) 2002-04-09 2011-06-08 フラメル・テクノロジー アモキシシリンの改変された放出のための、マイクロカプセルの水性懸濁液形態での経口医薬品製剤
CN100553625C (zh) 2002-04-09 2009-10-28 弗拉梅技术公司 活性成分微囊的口服混悬液
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
EP2112920B1 (fr) 2003-06-26 2018-07-25 Intellipharmaceutics Corp. Capsules contenant un inhibiteur de la pompe a protons comprenant des unites secondaires differemment structurees permettant une liberation retardee de l'ingredient actif
KR20060092255A (ko) 2003-09-26 2006-08-22 알자 코포레이션 고도의 약물적재를 제공하는 약물코팅제 및 그의 제조방법
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024362A1 (en) 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
WO2007112581A1 (fr) 2006-04-03 2007-10-11 Isa Odidi Dispositif d'administration à libération commandée comprenant un enrobage organosol
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
AU2007278986B2 (en) 2006-07-25 2010-09-16 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI
NZ598728A (en) 2006-12-22 2013-09-27 Ironwood Pharmaceuticals Inc Compositions comprising bile acid sequestrants for treating esophageal disorders
AU2009290712A1 (en) 2008-09-09 2010-03-18 Astrazeneca Ab Method for delivering a pharmaceutical composition to patient in need thereof
CA2764963C (fr) 2009-06-25 2016-11-01 Astrazeneca Ab Procede pour le traitement d'un patient a risque de developer un ulcere associe a nsaid
US20120294937A1 (en) 2009-12-29 2012-11-22 Novartis Ag New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080502A2 (fr) 2009-12-29 2011-07-07 Orexo Ab Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
WO2011080500A2 (fr) 2009-12-29 2011-07-07 Orexo Ab Nouvelle forme pharmaceutique destinée au traitement de troubles liés à l'acide gastrique
WO2012027331A1 (fr) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions et procédés pour traiter ou prévenir un syndrome métabolique et des maladies et troubles associés
EP2601947A1 (fr) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Combinaison à dose fixe pour le traitement de maladies associées à Hélicobacter pylori
BR112014016085A8 (pt) 2011-12-28 2017-07-04 Pozen Inc composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
MX383752B (es) 2013-01-15 2025-03-11 Ironwood Pharmaceuticals Inc Forma de dosificación oral de liberación sostenida gastro retentiva de un secuestrante de ácido biliar.
EP2801565B1 (fr) 2013-05-06 2015-07-22 King Saud University Composés destinés à être utilisés en tant qu'agent antiulcéreux et/ou agent anti-helicobacter pylori et leurs compositions pharmaceutiques
WO2016126625A1 (fr) 2015-02-03 2016-08-11 Ironwood Pharmaceuticals, Inc. Méthodes de traitement de troubles gastro-intestinaux supérieurs de gerd réfractaire à ppi

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4359465A (en) * 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
EP0174717B1 (fr) * 1984-07-06 1992-01-22 FISONS plc Benzimidazoles, et leur préparation, formulation et application comme inhibiteur de sécrétion d'acide gastrique

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4687775A (en) * 1986-07-17 1987-08-18 G. D. Searle & Co. 2-[(Imidazo[1,2-a]pyridinylmethyl)sulfinyl]-1H-benzimidazoles
US4772619A (en) * 1986-07-17 1988-09-20 G. D. Searle & Co. [(1H-benzimidazol-2-ylsulfinyl)methyl]-2-pyridinamines
US4721718A (en) * 1986-08-18 1988-01-26 G. D. Searle & Co. 2-[(imidazo[1,2-a]pyridin-3-ylmethyl)sulfinyl]-1H-benzimidazoles useful in the treatment and prevention of ulcers

Also Published As

Publication number Publication date
GB8521493D0 (en) 1985-10-02
SE8504048L (sv) 1986-03-01
NL8502384A (nl) 1986-03-17
GB2163747B (en) 1989-02-08
KR860001793A (ko) 1986-03-22
AU4640985A (en) 1986-03-06
KR920004936B1 (ko) 1992-06-22
CH665417A5 (fr) 1988-05-13
BR8504252A (pt) 1986-06-17
IT8567743A0 (it) 1985-08-30
AR242195A1 (es) 1993-03-31
DE3531487A1 (de) 1986-03-13
SE8504048D0 (sv) 1985-08-30
DE3531487C2 (de) 1995-08-17
ES546445A0 (es) 1986-11-16
ES8703142A1 (es) 1986-11-16
MX159807A (es) 1989-08-31
FR2569691B1 (fr) 1989-08-04
AU4127189A (en) 1989-12-21
GB2163747A (en) 1986-03-05
AU2975092A (en) 1993-01-28
AU647978B2 (en) 1994-03-31
IT1189601B (it) 1988-02-04
FR2569691A1 (fr) 1986-03-07
SE500669C2 (sv) 1994-08-08

Similar Documents

Publication Publication Date Title
BE903128A (fr) Derives de benzimidazole procede pour leur preparation et agents anti-ulceres en contenant
DE3677452D1 (de) Chinazolinderivate, verfahren zu deren herstellung und diese enthaltende pharmazeutische zusammensetzungen.
BE901224A (fr) Nouveaux derives d'indole utiles comme medicaments et intermediaires et procedes pour leur preparation.
BE1002211A4 (fr) (pentamethyl-1,2,2,6,6 piperidyl-4-amino)-triazines, leur application comme stabilisants de matieres organiques, et compositions qui en contiennent.
BE903778A (fr) Derives d'indoles.
SE8204817D0 (sv) Tetrazine derivatives
ATE41930T1 (de) Neue tryptamin-derivate, ein verfahren zu ihrer herstellung und ihre verwendung.
HUT37751A (en) Process for production of new, substituated prrolidinons
BE901987A (fr) Derives d'alcanolamines et inhibiteurs de l'agregation des plaquettes en contenant comme principe actif.
ATE179416T1 (de) 1-(arylalkyl-aminoalkyl) imidazolderivate, herstellungs verfahren und verwendung als therapeutische mittel
BE904641A (fr) 5-pyrimidine-carboxamides et traitement de la leucemie et des tumeurs avec ces derniers.
BE902710A (fr) Procede stereospecifique pour la preparation d'azetidinones.
BE900183A (fr) N-dichloracetyl-glycinamides substituees sur n et eventuellement sur n' et leur utilisation comme antidotes dans les herbicides.
BE1002181A3 (fr) 3-(2-haloalkyl)-1,4-oxathiines et 2-(2-haloalkyl)-1,4-dithiines, de meme que le traitement de la leucemie et des tumeurs avec ces substances.
BE905340A (fr) Derives du methylene-dioxy-phenanthrene et du stilbene, procede pour leur preparation et medicaments les contenant.
BE904409Q (fr) Nouveaux colorants cupriferes et leur preparation.
BE905297A (fr) Derives heterocycliques.
BE1003314A3 (fr) Procede de dedoublement d'intermediaires interessants dans la preparation de diltiazem.
BE904016A (fr) Nouveaux derives naphtaleniques du benzonorbornene, leur procede de preparation et compositions medicamenteuse et cosmetique les contenant
BE901072A (fr) Procede de decarbonylation selective.
BE900882A (fr) Derives de 2h-azeto(2,1-a)-isoquinoleine, procede pour les preparer et compositions pharmaceutiques les contenant.
BE900618A (fr) Derives de 4,5,6,7-tetrahydrobenzimidazole.

Legal Events

Date Code Title Description
RE Patent lapsed

Owner name: NIPPON CHEMIPHAR CO. LTD

Effective date: 20000831